Drug Trial Radar · NCT04965493
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Last checked: Nov 19, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Sep 20, 2021
Primary completion
Oct 2026
Study completion Oct 2027
Sponsor
- Lead sponsor
- Loxo Oncology, Inc.Eli Lilly (LLY)
- Sponsor type
- Industry
- Collaborators
- Eli Lilly and Company
- First posted
- Jul 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years.
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Interventions
PirtobrutinibDrug
Oral
VenetoclaxDrug
Oral
RituximabDrug
Intravenous (IV)
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate progression-free survival (PFS) of pirtobrutinib plus venetoclax and rituximab (Arm A) compared to venetoclax and rituximab (Arm B)Time frame: Up to approximately 5 years
Locations
176 sites in 23 countries. Site status is shown where the registry gives one.
Ironwood Physicians, Ironwood Cancer and Research Centers
Chandler, Arizona
Mayo Clinic Hospital
Phoenix, Arizona
University of California Irvine Medical Center
Orange, California
Scripps Mercy Hospital
San Diego, California
Providence Medical Foundation
Santa Rosa, California
Stamford Hospital
Stamford, Connecticut
Florida Cancer Specialists
Fort Myers, Florida
Cancer Specialists of North Florida -St Augustine
Saint Augustine, Florida
Florida Cancer Specialists East
West Palm Beach, Florida
Mission Cancer and Blood
Des Moines, Iowa
Pikeville Medical Center, Inc.
Pikeville, Kentucky
American Oncology Partners of Maryland, PA
Bethesda, Maryland
Dana-Farber Cancer Institute
Boston, Massachusetts
St. Joseph Mercy Hospital
Ann Arbor, Michigan
University of Michigan
Ann Arbor, Michigan
Mayo Clinic
Rochester, Minnesota
Research Medical Center
Kansas City, Missouri
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey
The Mount Sinai Hospital
New York, New York
Columbia University Medical Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Levine Cancer Institute
Charlotte, North Carolina
Novant Cancer Institute Charlotte
Charlotte, North Carolina
Duke University Medical Center
Durham, North Carolina
Regional Medical Oncology Center
Wilson, North Carolina
Oncology Hematology Care Inc
Cincinnati, Ohio
University Hospitals Cleveland Medical Center
Cleveland, Ohio
The James Cancer Hospital
Columbus, Ohio
Oncology Associates of Bridgeport P.C.
Eugene, Oregon
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Sarah Cannon Research Institute SCRI
Nashville, Tennessee
Tennessee Oncology PLLC
Nashville, Tennessee
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
USO - Texas Oncology - San Antonio
San Antonio, Texas
University of Virginia Health System
Charlottesville, Virginia
Virginia Cancer Specialists, PC - Lee Highway
Fairfax, Virginia
Virginia Commonwealth University Massey Cancer Center
Richmond, Virginia
Fred Hutchinson Cancer Research Center
Seattle, Washington
Swedish Cancer Institute; STE 1020
Seattle, Washington
Showing 40 of 176 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.